Latest news and press releases about OS Therapies Incorporated (OSTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.
Price
| Price | $1.75 |
| Market Cap | $80M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | -6.90 |
| EV / EBITDA | -2.15 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 683.03% |
| Return on Invested Capital | 350.07% |
| Return on Assets | -397.78% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADAG · COEP · CRVO · EQ · HOWL · INKT · IOBT
Explore sector: Healthcare · Biotechnology
More sections of OSTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks